A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma

References

• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G. D., Barcos M., Gottlieb A., O'Connell M. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Tirelli U., Errante D., Van Glabbeke M., Teodorovic I., Kluin-Nelemans J. C., Thomas J., Bron D., Rosti G., Somers R., Zagonel V., Noordijk E. M. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Journal of Clinical Oncology 1998; 16: 27–34
   PubMed Web of Science ®Google Scholar
• Montserrat E., Garcia-Conde J., Vinolas N., Lopez-Guillermo A., Hernandez-Nieto L., Zubizarreta A., Alacala A., Faura M. V., Llorente A., Blade J., Fontanillas M., Estape J. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. European Journal of Haematology 1996; 57: 377–383
   PubMed Web of Science ®Google Scholar
• Cooper I. A., Wolf M. M., Robertson T. I., Fox R. M., Matthews J. P., Stone J. M., Ding J. C., Matthews J., Firkin F. C., Lowenthal R. M., Ironside P. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Journal of Clinical Oncology 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Sonneveld P., De Ridder M., Van der Lelie H., Nieuwenhuis K., Schouten H., Mulder A., Van Reijswoud I., Hop W., Lowenberg B. Comparison of doxorubicin and mitoxanthrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Journal of Clinical Oncology 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• McKelvey E. M., Gottlieb J. A., Wilson H. E., Haut A., Talley R. W., Stephens R., Lane M., Gamble J. F., Jones S. E., Grozea P. N., Gutterman J., Coltman C., Moon T. E. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller F, Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M, Stewart M., Glaspy J. Reduction by granulocyte-colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-metHuG-CSF). New England Journal of Medicine 1991; 325: 164–170
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V., Green J., Manegold C., Van Pawell J., Gatzemeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 1993; 29A: 319–324
   PubMed Web of Science ®Google Scholar
• Pettengell R., Gurney H., Radford J. A., Deakin D. P., James R., Wilkinson P. M., Kane K., Bentley J., Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Eagles E. A., Barza L. J. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. Journal of Clinical Oncology 1998; 16: 1179–1187
   PubMed Web of Science ®Google Scholar
• Cruciani M., Rampazzo R., Malena M., Lazzarini L., Todeschini G., Messori A., Concia E. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clinical Infectious Diseases 1996; 23: 795–805
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Rubin P., Keys H. The staging and classification of cancers: a unified approach. Principles of Cancer Treatment, S. K. Carter, E. Glatstein, R. B.R.B. Livingston. McGraw-Hill, New York 1982; 22
   Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodg-kin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966; 64: 328–340
   PubMed Web of Science ®Google Scholar
• Hansen P. B., Johnsen H. E., Ralfkiaer E., Jansen L., Gaarsdal E., Hansen N. E. Short term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas. Leukemia and Lymphoma 1994; 19: 453–460
   Web of Science ®Google Scholar
• Hoagland H. C. Hematologic complications of cancer chemotherapy. Seminars in Oncology 1982; 9: 95–102
   PubMed Web of Science ®Google Scholar
• Jagannath S., Velasquez W. S., Tucker S. L., Fuller J. M., McLaughlin P. W., Manning J. T., North L. B., Cabanillas F. C. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. Journal of Clinical Oncology 1986; 4: 859–865
   PubMed Web of Science ®Google Scholar
• Srigley J., Barlogie B., Butler J. J., Osborne B., Blick M., Johnston D., Kantarjian H., Reuben J., Batsakis J., Freireich E. J. Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry. Blood 1985; 65: 1090–1096
   PubMed Web of Science ®Google Scholar
• Chlebowski R. T. Effect of nutritional support on the outcome of antineoplastic therapy. Clinical Oncology 1986; 5: 365–379
   Google Scholar
• Flanigen-Roat D. T., Milholland R. J., Ip M. M. Effect of a high-protein-low-carbohydrate diet on toxicity and antitumor activity of 5-fluorouracil in mice. Journal of National Cancer Institute 1985; 74: 705–710
   PubMed Web of Science ®Google Scholar
• Cowan R. A., Jones M., Harris M., Steward W. P., Radford J. A., Wagstaff J., Deakin D. P., Crowther D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. British Journal of Cancer 1989; 59: 276–282
   PubMed Web of Science ®Google Scholar
• Watkins S. M. Predicting neutropenia after chemotherapy for lymphoma. Leukemia and Lymphoma 1993; 9: 107–109
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D., Bierman P. J., Sorensen S., Hutchins M., Moravec D. F., Howe D., Dowling M. D., Mailliard J., Johnson P. S., Pevnick W., Packard W. M., Okerbloom J., Thomson R. F., Laugdon R. M., Soori G., Peterson C. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Dixon O. D., Neilan B., Jones S. E., Lipschitz D. A., Miller T. P., Grozea P. N., Wilson H. E. Effect on age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T., Wannakrairoj P., Chaimongkol B., Bhoopat L., Lekhakula A., Thamprasit T., Suwanwela N., Suthipinthawong C., Prayoonwiwat W., Meekungwal P., Sirijerachai C., Pairotkul C. Non-Hodgkin's lymphomas in Thailand: a retrospective pathologic and clinical analysis of 1391 cases. Cancer 1996; 78: 1813–1819
   PubMed Web of Science ®Google Scholar
• Harrington D. S., Ye Y., Weisenburger D. D., Armitage J. O., Pierson J., Bast M., Purtilo D. T. Malignant lymphoma in Nebraska and Guangzhou, China: a comparative study. Human Pathology 1987; 18: 924–928
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T., Prayoonwiwat W., Swasdikul D., Suwanwela N., Chaimongkol B., Jootar S., Chansung K., Chancharunee S., Leelasiri A., Yoshida Y. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leukemia Research 1998; 22: 453–460
   PubMed Web of Science ®Google Scholar
• Jootar S., Ungkanont A., Chuncharunee S., Atichar-Takarn V. Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia: an update of the first series in Thailand. Asian Pacific Journal of Allergy and Immunology 1996; 14: 25–30
   PubMed Web of Science ®Google Scholar